LYZL1 Inhibitors
LYZL1 inhibitors belong to a class of chemical compounds specifically designed to target and modulate the activity of lysozyme-like 1 (LYZL1), a protein implicated in various biological processes. LYZL1, a member of the lysozyme family, plays a crucial role in innate immune responses and has been identified in multiple tissues, including the testis, where it is predominantly expressed. The development of LYZL1 inhibitors stems from the recognition of the protein's involvement in key physiological functions, and researchers have sought to elucidate the intricate mechanisms through which these inhibitors interact with LYZL1.
These inhibitors are characterized by their ability to selectively bind to LYZL1, modulating its enzymatic activity or interfering with its interactions with other biomolecules. The structural features of LYZL1 inhibitors are carefully designed to ensure a high degree of specificity, aiming to minimize off-target effects. Understanding the intricate details of the molecular interactions between LYZL1 and its inhibitors is crucial for the rational design of potent compounds. Ongoing research in this field focuses on elucidating the precise binding sites and structural motifs that govern the efficacy of LYZL1 inhibitors, laying the groundwork for the development of next-generation compounds with enhanced bioavailability and improved pharmacokinetic profiles. The exploration of LYZL1 inhibitors represents a promising avenue in chemical biology, offering insights into the molecular underpinnings of immune responses and contributing to the broader understanding of protein function within various biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E64d is an irreversible cysteine protease inhibitor. Given that LYZL1 has a structure similar to that of lysozymes, which are a type of hydrolase, E64d could indirectly inhibit LYZL1 by blocking the cysteine residues in the active site, thereby preventing substrate cleavage. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is a reversible inhibitor of serine and cysteine proteases. Its use could result in an accumulation of proteins in lysosomal pathways, potentially causing an indirect inhibition of LYZL1 by altering the lysosomal environment, where LYZL1 is thought to function. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase. By preventing acidification of the lysosome, it could indirectly inhibit LYZL1 action as the protein may require an acidic pH for its optimal lysosomal activity, particularly if its function is similar to that of lysozymes. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole is a proton pump inhibitor that can elevate the pH in acidic compartments. If LYZL1 operates optimally in acidic environments, such as lysosomes, omeprazole could indirectly inhibit its function by reducing the acidity, thus impacting the degradation process where LYZL1 might be involved. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a broad-spectrum caspase inhibitor. By inhibiting caspases, it could indirectly affect the turnover of proteins within the cell, potentially leading to an altered intracellular environment that could indirectly affect LYZL1's functional stability or interaction with other proteins. | ||||||
Phosphoramidon | 119942-99-3 | sc-201283 sc-201283A | 5 mg 25 mg | $199.00 $632.00 | 8 | |
Phosphoramidon is a metalloprotease inhibitor. It could indirectly inhibit LYZL1 by inhibiting metalloproteases that might process or activate proteins in the same pathway or cellular compartment as LYZL1, thus potentially altering LYZL1 activity through these protein-protein interactions. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor. By preventing the degradation of proteins, it could lead to an accumulation that indirectly impacts LYZL1, possibly by competitive inhibition or by affecting the overall protein composition within the lysosome, where LYZL1 may be active. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A is another inhibitor of the vacuolar H+-ATPase. It could indirectly inhibit LYZL1 by disrupting lysosomal acidification, leading to an environment that is not conducive to the enzymatic activity of LYZL1 if it requires a low pH for its lysozyme-like action. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome. It could indirectly inhibit LYZL1 by blocking proteasomal degradation, resulting in the accumulation of proteins that could influence the environment or regulatory processes in which LYZL1 is involved, thereby affecting its activity. | ||||||